This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy combinations and the promise of several novel immunotherapies, including anti-IDO1 checkpoint blockade and a personalized, patient-specific vaccine. Other measures of immunotherapy’s effectiveness, such as patient quality of life, were also discussed. Below are some of the most important findings that were revealed today:
Multiple Tumor Types:
Bladder Cancer:
Brain Cancer:
Breast Cancer:
Esophageal Cancer:
Head and Neck Cancer:
Kidney Cancer:
Leukemia:
Lung Cancer:
Melanoma / Skin Cancers:
Sarcoma:
Stomach & Gastrointestinal Cancer:
ASCO17: Day 1 Immunotherapy Highlights
Read Previous Article
ASCO17: Day 3 Immunotherapy Highlights
Read Next Article
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.
Immunotherapy updates from the world's largest cancer conference, the Annual Meeting of the American Society for Clinical Oncology (ASCO).